The companies will develop an AI-augmented, integrated technology platform, that will enable multiobjective, polypharmacology-informed drug design. Cerevel will use Cyclica's Ligand Express and Ligand Design AI platforms to identify potential leads for new medicines, the two firms said.

The platform will be used to screen, identify, design, and evaluate compounds. Cerevel has at least five clinical and seven preclinical pipelines for several neurological indications under development utilizing the platform. Cyclica's AI platform will help accelerate drug discovery and in silico drug design of Cerevel's targets.

Fox Chase creates AI program for virtual drug screening
Fox Chase Cancer Center researchers have developed a new artificial intelligence (AI) program that could make virtual screening for cancer drugs more...

From DNA to precision medicine, researchers discuss breakthroughs in cancer research
From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer,...

Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly...